{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:42:13Z","timestamp":1784612533340,"version":"3.55.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010883","name":"Traditional Chinese Medicine Bureau of Guangdong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010883","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background and Aim:<\/jats:bold> Tacrolimus (TAC) is a first-line immunosuppressant for the treatment of refractory nephrotic syndrome (RNS), but the pharmacokinetics of TAC varies widely among individuals, and there is still no accurate model to predict the pharmacokinetics of TAC in RNS. Therefore, this study aimed to combine population pharmacokinetic (PPK) model and machine learning algorithms to develop a simple and accurate prediction model for TAC.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> 139 children with RNS from August 2013 to December 2018 were included, and blood samples of TAC trough and partial peak concentrations were collected. The blood concentration of TAC was determined by enzyme immunoassay; <jats:italic>CYP3A5<\/jats:italic> was genotyped by polymerase chain reaction-restriction fragment length polymorphism method; <jats:italic>MYH9<\/jats:italic>, <jats:italic>LAMB2<\/jats:italic>, <jats:italic>ACTN4<\/jats:italic> and other genotypes were determined by MALDI-TOF MS method; PPK model was established by nonlinear mixed-effects method. Based on this, six machine learning algorithms, including eXtreme Gradient Boosting (XGBoost), Random Forest (RF), Extra-Trees, Gradient Boosting Decision Tree (GBDT), Adaptive boosting (AdaBoost) and Lasso, were used to establish the machine learning model of TAC clearance.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A one-compartment model of first-order absorption and elimination adequately described the pharmacokinetics of TAC. Age, co-administration of Wuzhi capsules, <jats:italic>CYP3A5<\/jats:italic> *3\/*3 genotype and <jats:italic>CTLA4<\/jats:italic> rs4553808 genotype were significantly affecting the clearance of TAC. Among the six machine learning models, the Lasso algorithm model performed the best (R<jats:sup>2<\/jats:sup> = 0.42).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> For the first time, a clearance prediction model of TAC in pediatric patients with RNS was established using PPK combined with machine learning, by which the individual clearance of TAC can be predicted more accurately, and the initial dose of administration can be optimized to achieve the goal of individualized treatment.<\/jats:p>","DOI":"10.3389\/fphar.2022.942129","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T07:25:05Z","timestamp":1668497105000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Tacrolimus pharmacokinetics in pediatric nephrotic syndrome: A combination of population pharmacokinetic modelling and machine learning approaches to improve individual prediction"],"prefix":"10.3389","volume":"13","author":[{"given":"Qiongbo","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewei","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangling","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"B1","first-page":"707","article-title":"Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture","volume":"44","author":"Abdel-Razzak","year":"1993","journal-title":"Mol. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ekir.2019.09.009","article-title":"Predicting and defining steroid resistance in pediatric nephrotic syndrome using plasma proteomics","volume":"5","author":"Agrawal","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical Pharmacogenetics implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/jvp.12473","article-title":"Mathematical modeling and simulation in animal health. Part III: Using nonlinear mixed-effects to characterize and quantify variability in drug pharmacokinetics","volume":"41","author":"Bon","year":"2018","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/jcph.1325","article-title":"Population pharmacokinetics of tacrolimus in transplant recipients: What did we learn about sources of interindividual variabilities?","volume":"59","author":"Campagne","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1080\/00498254.2019.1669844","article-title":"Optimization of initial dosing scheme of tacrolimus in pediatric refractory nephrotic syndrome patients based on CYP3A5 genotype and coadministration with wuzhi-capsule","volume":"50","author":"Chen","year":"2020","journal-title":"Xenobiotica."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1111\/jcpt.13493","article-title":"Effects and safety evaluation of Wuzhi Capsules combined with tacrolimus for the treatment of kidney transplantation recipients","volume":"46","author":"Cheng","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.coi.2012.12.003","article-title":"T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment","volume":"25","author":"Crespo","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/s0006-2952(98)00372-4","article-title":"Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy","volume":"57","author":"Elkahwaji","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/psp4.12392","article-title":"A theoretical physiologically-based pharmacokinetic approach to ascertain covariates explaining the large interpatient variability in tacrolimus disposition","volume":"8","author":"Emoto","year":"2019","journal-title":"CPT. Pharmacometrics Syst. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1126\/science.286.5439.487","article-title":"Pharmacogenomics: Translating functional genomics into rational therapeutics","volume":"286","author":"Evans","year":"1999","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1681\/asn.2019101032","article-title":"Phosphorylation of ACTN4 leads to podocyte vulnerability and proteinuric glomerulosclerosis","volume":"31","author":"Feng","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.phrs.2016.07.015","article-title":"Pharmacokinetics interactions of monoclonal antibodies","volume":"111","author":"Ferri","year":"2016","journal-title":"Pharmacol. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"E2517","DOI":"10.3390\/ijms21072517","article-title":"A machine learning-based identification of genes affecting the pharmacokinetics of tacrolimus using the DMET(TM) plus platform","volume":"21","author":"Gim","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1111\/bcp.13605","article-title":"Population pharmacokinetics of tacrolimus in children with nephrotic syndrome","volume":"84","author":"Hao","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"105199","DOI":"10.1016\/j.ejps.2019.105199","article-title":"Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: A comparison of linear and nonlinear michaelis-menten pharmacokinetic model","volume":"143","author":"Huang","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2147\/dddt.S41349","article-title":"Tacrolimus in preventing transplant rejection in Chinese patients--optimizing use","volume":"9","author":"Li","year":"2015","journal-title":"Drug Des. devel. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"107827","DOI":"10.1016\/j.intimp.2021.107827","article-title":"Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome","volume":"98","author":"Li","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/aps.2016.153","article-title":"IL-3 and CTLA4 gene polymorphisms may influence the tacrolimus dose requirement in Chinese kidney transplant recipients","volume":"38","author":"Liu","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"B20","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00467-012-2310-x","article-title":"Treatment of steroid-sensitive nephrotic syndrome: New guidelines from KDIGO","volume":"28","author":"Lombel","year":"2013","journal-title":"Pediatr. Nephrol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1111\/bcp.14842","article-title":"Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus\u00ae) in stable adult liver transplant recipients","volume":"87","author":"Martial","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2147\/pgpm.S339318","article-title":"Prediction of tacrolimus dose\/weight-adjusted trough concentration in pediatric refractory nephrotic syndrome: A machine learning approach","volume":"15","author":"Mo","year":"2022","journal-title":"Pharmgenomics. Pers. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41397-019-0141-x","article-title":"Kidney podocyte-associated gene polymorphisms affect tacrolimus concentration in pediatric patients with refractory nephrotic syndrome","volume":"20","author":"Mo","year":"2020","journal-title":"Pharmacogenomics J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/s0140-6736(18)30536-1","article-title":"Idiopathic nephrotic syndrome in children","volume":"392","author":"Noone","year":"2018","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.gene.2018.04.048","article-title":"MYH9: Structure, functions and role of non-muscle myosin IIA in human disease","volume":"664","author":"Pecci","year":"2018","journal-title":"Gene"},{"key":"B26","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ijpharm.2010.01.025","article-title":"Mechanistic understanding of the different effects of Wuzhi Tablet (Schisandra sphenanthera extract) on the absorption and first-pass intestinal and hepatic metabolism of Tacrolimus (FK506)","volume":"389","author":"Qin","year":"2010","journal-title":"Int. J. Pharm."},{"key":"B27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1124\/dmd.113.053892","article-title":"In vivo to in vitro effects of six bioactive lignans of Wuzhi tablet (Schisandra sphenanthera extract) on the CYP3A\/P-glycoprotein-mediated absorption and metabolism of tacrolimus","volume":"42","author":"Qin","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1172\/jci20402","article-title":"Induction of B7-1 in podocytes is associated with nephrotic syndrome","volume":"113","author":"Reiser","year":"2004","journal-title":"J. Clin. Invest."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s40262-021-01033-x","article-title":"Drug clearance in neonates: A combination of population pharmacokinetic modelling and machine learning approaches to improve individual prediction","volume":"60","author":"Tang","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"42192","DOI":"10.1038\/srep42192","article-title":"Application of machine-learning models to predict tacrolimus stable dose in renal transplant recipients","volume":"7","author":"Tang","year":"2017","journal-title":"Sci. Rep."},{"key":"B31","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/s1074-7613(00)80366-0","article-title":"The emerging role of CTLA-4 as an immune attenuator","volume":"7","author":"Thompson","year":"1997","journal-title":"Immunity"},{"key":"B32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/cpt.2326","article-title":"Machine learning as a novel method to support therapeutic drug management and precision dosing","volume":"110","author":"van Gelder","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.3892\/etm.2019.7446","article-title":"Population pharmacokinetics of tacrolimus in pediatric refractory nephrotic syndrome and a summary of other pediatric disease models","volume":"17","author":"Wang","year":"","journal-title":"Exp. Ther. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"125","DOI":"10.5414\/cp203355","article-title":"Population pharmacokinetics and dosage optimization of tacrolimus in pediatric patients with nephrotic syndrome","volume":"57","author":"Wang","year":"","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1124\/dmd.112.050302","article-title":"Effects of traditional Chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats","volume":"41","author":"Wei","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"B36","doi-asserted-by":"publisher","first-page":"105578","DOI":"10.1016\/j.phrs.2021.105578","article-title":"Estimation of drug exposure by machine learning based on simulations from published pharmacokinetic models: The example of tacrolimus","volume":"167","author":"Woillard","year":"2021","journal-title":"Pharmacol. Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1007\/s11095-022-03273-3","article-title":"Population pharmacokinetic evaluation with external validation of tacrolimus in Chinese primary nephrotic syndrome patients","volume":"39","author":"Yang","year":"2022","journal-title":"Pharm. Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1304572","article-title":"Abatacept in B7-1-positive proteinuric kidney disease","volume":"369","author":"Yu","year":"2013","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.942129\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T07:25:10Z","timestamp":1668497110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.942129\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":38,"alternative-id":["10.3389\/fphar.2022.942129"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.942129","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,15]]},"article-number":"942129"}}